Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Total Liabilities (2020 - 2026)

MoonLake Immunotherapeutics' Total Liabilities history spans 7 years, with the latest figure at $146.4 million for Q1 2026.

  • Quarterly Total Liabilities rose 48.31% to $146.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $146.4 million through Mar 2026, up 48.31% year-over-year, with the annual reading at $120.0 million for FY2025, 388.76% up from the prior year.
  • Total Liabilities came in at $146.4 million for Q1 2026, up from $120.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $206.8 million in Q1 2022 to a low of $3.9 million in Q2 2022.
  • The 5-year median for Total Liabilities is $14.8 million (2024), against an average of $54.6 million.
  • Year-over-year, Total Liabilities skyrocketed 4962.8% in 2022 and then crashed 96.28% in 2023.
  • MoonLake Immunotherapeutics' Total Liabilities stood at $8.1 million in 2022, then surged by 61.57% to $13.0 million in 2023, then surged by 88.07% to $24.5 million in 2024, then surged by 388.76% to $120.0 million in 2025, then increased by 22.01% to $146.4 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Total Liabilities are $146.4 million (Q1 2026), $120.0 million (Q4 2025), and $123.1 million (Q3 2025).